Next, we assessed the stability and therapeutic efficacy of a targeted “off-the-shelf” allogeneic-engineered MSC specifically engineered to target DR4/DR5 in GBM tumor cells (MSCBif). The gene discussed is TNFRSF10A; the disease is neoplasm.